Awards to recognise best in UK pharma

AstraZeneca, Bristol-Myers Squibb and Boehringer Ingelheim will be among the finalists for the 2016 UK Prix Galien Awards, which celebrate the most innovative products in pharma.

There are three categories this year – the Innovative Product Award, the Orphan Product Award, and the Real World Evidence award.

The biennial UK Prix Galien awards are the UK franchise of the larger global initiative recognising the best in pharma research.

Other finalists include MSD, Sanofi Genzyme, Celgene, Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda.

The Innovative Product Award is open to new medicines launched or granted a new indication in the UK market during the period 1 January 2014 to 31 March 2016. Products granted marketing authorisation through EU centralised procedure, in the UK or available under the mutual recognition process are admissible.

The Orphan Product Award is open to innovative new products granted orphan status in the European Union and/or the US, launched or granted a new indication in the UK market during the period 1 January 2014 to 31 March 2016.

The new Real World Evidence Award recognises excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patient benefits or socio-economic gains in licensed medicines. It is open to previous UK Prix Galien winners and commended products only.

The panel of judges is chaired by Sir Michael Rawlins, who is also the chair of the UK’s Medicines and Healthcare Products Regulatory Agency.

Vice chair is Parveen Kumar, former president of the British Medical Association and of the Royal Society of Medicine.

Also on the panel is professor Sir Mike Richards, who is chief inspector of hospitals in England.

The awards this year are run by ValueBase, who own the UK Prix Galien franchise.

Full details of the finalists at the awards ceremony, which will be held at the Houses of Parliament in September, are available here.